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Abstract
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of disease ranging from simple steatosis to inflammatory
steatohepatitis (NASH) with different degrees of fibrosis that can ultimately progress to cirrhosis. Accumulating evidence
suggests the involvement of the endocannabinoid-system in liver disease and related complications. In particular,
hepatoprotective properties for Cannabinoid Receptor type 2 (CB2) have been shown both through experimental murine
models of liver injury and association study between a CB2 functional variant, Q63R, and liver enzymes in Italian obese
children with steatosis. Here, in order to clarify the role of CB2 in severity of childhood NAFLD, we have investigated the
association of the CB2 Q63R variant, with histological parameters of liver disease severity in 118 Italian children with
histologically-proven NAFLD. CB2 Q63R genotype was assigned performing a TaqMan assay and a general linear model
analysis was used to evaluate the association between the polymorphism and the histological parameters of liver
damage. We have found that whereas CB2 Q63R variant is not associated with steatosis or fibrosis, it is associated with the
severity of the inflammation (p= 0.002) and the presence of NASH (p= 0.02). Our findings suggest a critical role for CB2
Q63R variant in modulating hepatic inflammation state in obese children and in the consequent increased predisposition of
these patients to liver damage.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum
of disease ranging from simple steatosis to inflammatory
steatohepatitis (NASH) with different degrees of fibrosis that can
ultimately progress to cirrhosis [1,2]. Its prevalence is estimated to
be between 20% and 30% in Western adults, rising to 90% in the
morbidly obese. Of concern, NAFLD affects 2% to 10% of
children and adolescents, this prevalence rising to 80% in obese
children [3,4].
Evidence that only a minority of patients with NAFLD progress
to NASH suggests that disease progression is likely to depend on
complex interplay between environmental factors and genetic
predisposition [5]. Indeed, genetic variants in genes involved in
energy balance, such as adiponutrin/patatin-like phospholipase
domain-containing 3 (PNPLA3) and apolipoprotein C3 (APOC3),
or in genes involved in inflammation, oxidative stress and
fibrogenesis, such as SOD2, have been demonstrated to be
associated with NAFLD and the severity of liver damage [6–8].
Cannabinoid receptors (CBs) are seven-transmembrane domain
G protein-coupled receptors that bind phyto-derived, as well as
endogenous cannabinoids, among which anandamide (AEA) and
2-arachidonoylglycerol (2-AG) are the best characterized. Two
types of CBs are known to date, namely CB1 and CB2,
respectively. CB1 are expressed at high levels in the central
nervous system (CNS), whereas CB2 are found predominantly, but
not exclusively, outside the CNS. CBs, together with the enzymes
metabolizing AEA and 2-AG, form the endocannabinoid (EC)
system [9,10].
The EC system is involved in a wide range of regulatory
functions and is now emerging as critical mediator of both acute
and chronic liver injury [11]. This has been demonstrated by
several preclinical models of nonalcoholic and alcoholic fatty liver,
fibrosis, liver ischemia and cirrhosis showing that pharmacological
modulation of EC system is effective in reducing liver injury [12–
14].
Particularly, hepatoprotective and antifibrogenic properties
have been recently suggested for CB2 receptors both through
experimental murine models of liver injury and association study
between a common functional variant of CB2, Q63R, with liver
enzymes in a cohort of 438 Italian obese children with steatosis at
ultrasound imaging [15–17].
In order to clarify the role of CB2 in severity of childhood
NAFLD, in this study we have investigated the association of the
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Q63R CB2 variant with histological parameters of liver damage in
a large series of Italian children with biopsy-proven NAFLD.
Materials and Methods
Patients
This study was carried on 118 consecutive untreated children
and adolescents (41 males and 77 females) with biopsy-proven
NAFLD who were referred to Bambino Gesu` Children’s Hospital
between May 2006 and November 2009 [18,19]. Secondary
causes of steatosis such as alcohol abuse (more than 140 g/week),
total parenteral nutrition, the use of drugs known to precipitate
steatosis (e.g., valproate, amiodarone, and prednisone) and virus
infections (Hepatitis A, B, C, D, cytomegalovirus, and Epstein-
Barr) were excluded by appropriate tests. Autoimmune liver
disease, metabolic liver disease, Wilson disease, and alpha-1-
antitrypsin were ruled out with standard clinical and laboratory
evaluations and/or through liver biopsy. All enrolled patients were
Caucasians of Italian descent. The study was performed according
to the recommendations of the ethics committee of Bambino Gesu`
Hospital and was conformed to the ethical guidelines of the 1975
Declaration of Helsinki. Informed consent from parents and assent
from each patient were obtained.
Anthropometric and biochemical investigations, as well as
evaluation of histology on liver biopsies were performed as
previously described [18,19]. Liver biopsy samples were at least
18 mm long and were read by a single liver pathologist who was
unaware of the clinical and laboratory data of the patients. Biopsy
samples were routinely processed (formalin- fixed and paraffin-
embedded) and stained with hematoxylin and eosin and Van
Gieson stains for the assessment of fibrosis and architectural
changes.
The diagnosis of NASH was based on the pathologist’s overall
impression according to Kleiner et al. [20]. The main histological
features commonly described for NAFLD, including steatosis,
inflammation (both portal and lobular), hepatocyte ballooning,
and fibrosis, were scored according to the scoring system for
NAFLD as previously described [19]. Steatosis was graded on a
four-point scale: 0) steatosis involving fewer than 5% of
hepatocytes, 1) steatosis involving up to 33% of hepatocytes, 2)
steatosis involving 33% to 66% of hepatocytes, and 3) steatosis
involving more than 66% of hepatocytes. Lobular inflammation
was also graded on a four point scale: 0) no foci, 1) fewer than two
foci per field, 2) two to four foci per field, and 3) more than four
foci per field. Hepatocyte ballooning was graded from 0 to 2: 0) no
balloon cells, 1) few balloon cells, and 2) many/prominent balloon
cells. The stage of fibrosis was quantified with a five-point scale: 0)
no fibrosis, 1) perisinusoidal or periportal fibrosis [1a) mild, zone 3,
perisinusoidal; 1b) moderate, zone 3, perisinusoidal; and 1c)
portal/periportal], 2) perisinusoidal and portal/periportal fibrosis,
3) bridging fibrosis, and 4) cirrhosis.
Steatosis, inflammation, hepatocyte ballooning, and fibrosis
were scored using the NAFLD Clinical Research Network (CRN)
criteria [20]. Features of steatosis, lobular inflammation, and
hepatocyte ballooning were combined to obtain the NAFLD
activity score (NAS).
As recommended by a recent NASH CRN article [21], a
microscopic diagnosis, based on overall injury pattern (i.e.,
steatosis, hepatocyte ballooning, and inflammation), as well as
the presence of additional lesions (e.g., zonality of lesions, portal
inflammation, and fibrosis), has been assigned to each case [22].
Accordingly, biopsies were subdivided into not steatohepatitis (not-
SH) and definite steatohepatitis (definite-SH) subcategories [22].
Genetic Analysis
After a written informed consent from parents and assent from
children were obtained, genomic DNA was extracted from
peripheral whole blood with a DNA extraction kit (Promega,
Madison WI). Detection of the CNR2 rs35761398 polymorphism
(CAA/CGG), underlying the Q63R CB2 substitution, was
performed by using a TaqMan Assay (Real Master Mix Probe,
5 PRIME, Germany).
Primers and probes were the following: Sense Primer 59-
GTGCTCTATCTGATCCTGTC-39 and Anti-sense primer 59-
TAGTCACGCTGCCAATC-39; AA-Probe 59-CCCAC-
CAACTCCGC-39 and GG-Probe 59-CCCACCGGCTCCG-39
(PRIMM, Milan, Italy). Both polymerase chain reaction, per-
formed according to the manufacturer’s instruction, and post–
polymerase chain reaction allelic discrimination through the
measurement of allele-specific fluorescence were carried out on
an ABIPRISM 9600 apparatus (Applied Biosystem, Foster City,
CA). Random samples were confirmed by direct genotyping
performing a PCR consisting in 94uC for 4 min followed by 31
cycles of 94uC for 30 s, 60uC for 30 s and 72uC for 30 s with
Forward 59-GAGTGGTCCCCAGAAGACAG-39 and Reverse
59-CACAGAGGCTGTGAAGGTCA-39 primers. PCR products
were analysed by using an ABI PRISM 3100 automated sequencer
(Applied Biosystem, Foster City, CA). All primers were picked by
using Primer3 software.
Patients were also screened, as previously described [23], for
I148M PNPLA3 variant.
Statistical Analysis
Results are expressed as means 6 standard deviations. Mean
values were compared by analysis of ANOVA, followed by
Student–Newman–Keuls post hoc test. The differences in
genotype and allelic frequencies and the association between the
Q63R CB2 polymorphism with different clinical and liver
histological parameters were evaluated by general linear model
analysis including gender, age, waist circumference and HOMA-
IR as covariates. Moreover we performed a multiple test including
PNPLA3 genotype as covariate and then a multivariate analysis
incorporating I148M PNPLA3 as well as Q63R CB2 variants for
the whole cohort. Analyses were carried out by using Stat-Graph
3.0 software. In all cases p-values less than 0.05 were considered to
be statistically significant.
Results
To determine the influence of the Q63R variant on suscepti-
bility to NASH, we examined whether this variant was associated
with histological parameters of liver disease severity in a cohort of
children with biopsy-proven NAFLD. Clinical and histological
data of the children involved in the study are reported in Table 1.
As expected the great majority of the children was obese.
The frequency distribution of the Q63R CB2 SNP was in
Hardy-Weinberg equilibrium. Heterozygosity for the at-risk allele
encoding for R was observed in 39% of patients, and homozy-
gosity was observed in 50%.
The Q63R genotype was not significantly associated with body
mass index, lipid levels, insulin resistance, insulin sensitivity index,
AST, ALT and gamma-GT levels (Table 2).
A weak association was found with HOMA-IR index. Since the
degree of insulin resistance is known to affect both severity of
lobular inflammation and NASH, in the statistical analysis
performed on liver histological data, beside age, sex and waist
circumference, we added HOMA-IR index as covariate.
Cannabinoid Receptor Type 2 and Pediatric NAFLD
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The Q63R genotype was strongly associated with the severity of
inflammation. Grade 2 of inflammation was observed in 0 of 13
children with the QQ genotype, in 10 of 46 with the QR genotype
(22%), and in 13 of 59 with the RR genotype (22%) (p= 0.0022;
Fig. 1A).
The Q63R SNP was not associated with the severity of steatosis
(grades 0–3) (p= 0.07; Fig. 1B), or of fibrosis (grades 0–3) (p= 0.24;
Fig. 1C), neither with the ballooning (p= 0.93; not shown).
The prevalence of NASH according to the Q63R CB2 variant
is shown in Figure 2A. Among children with NASH, 4% (2/53)
had QQ genotype, 43% (23/53) showed QR genotype, whereas
the remaining 53% (28/53) were RR homozygous (p= 0.02).
The relative odds ratios are shown in Table S1.
We also investigated the role of I148M PNPLA3 variant on
NAFLD severity and, according to previous report [19], we found
that subjects homozygous for I148 PNPLA3 variant were
completely protected from NASH, whereas all M148 PNPLA3
homozygous patients showed definitive NASH. NASH was
present in the 70% (38 out of 55) of I148M heterozygous subjects.
When the PNPLA3 genotype was included in the multivariate
analysis the association between Q63R genotype and the severity
of inflammation or the presence of NASH did not appear still
significant (p= 0.069 and p= 0.12, respectively).
Performing a multivariate analysis incorporating both I148M
PNPLA3 and Q63R CB2 variants, as well as age, sex, waist
circumference and HOMA-IR, the association with inflammation
and steatosis, driven by the PNPLA3 genotype, was significant
(p,1024), whereas the association with fibrosis was not (p= 0.08)
(Table S2).
When we stratified the sub-group of 55 children I148M
PNPLA3 heterozygous for the Q63R CB2 variant, we found that
the presence of NASH among these patients was significantly
associated to the presence of the R63 CB2 allele (p= 0.001; Fig. 2B)
and that the odds ratio-associated p value was 0.0001.
Discussion
Considering that only a portion of patients with NAFLD will
progress from simple fatty liver (steatosis) to inflammation
(steatohepatitis), fibrosis and ultimately cirrhosis, it appears as an
important goal to understand the mechanisms leading to this
progression [24]. Data from literature evidence that this progres-
sion is triggered by a number of factors, such as oxidative stress,
endoplasmic reticulum stress, fatty acid lipotoxicity, immune
system activation, inflammatory cytokine production, possibly able
to determine the different spectrum of disease [25].
It has been shown in rodents that the setting of simple hepatic
steatosis is associated with a chronic hepatic inflammatory state,
due to increased activation of the nuclear factor kB (NF-kB)
transcription factor which, in turn, functioning as a pro-
Table 1. Clinical and Laboratory Characteristics of the 118
Italian Pediatric Patients with biopsy-proven NAFLD.










IGT or diabetes 59 (50)





NASH (presence) 53 (45)
Inflammation stage (G0/G1/G2) 3/92/23 (2.5/79/19.5)
Steatosis stage (G0/G1/G2/G3) 1/43/56/18 (1/36.5/47.5/15)
Fibrosis stage (G0/G1/G2/G3) 38/67/7/6 (32/57/6/5)
CB2 Q63R variant (QQ/QR/RR) 13/46/59 (11/39/50)





Values are expressed as means6 standard deviations. Abbreviations: BMI: Body
Mass Index; HOMA-IR: homeostatic model of assessment of insulin resistance;
ISI: insulin sensitivity index; IGT: Impaired Glucose Tolerance; ALT: alanine
transaminase; AST: aspartate transaminase; Gamma-GT: Gamma-Glutamyl
transferase; NASH: nonalcoholic steatohepatitis; G = grading.
doi:10.1371/journal.pone.0042259.t001
Table 2. Clinical and laboratory characteristics of the 118
Italian children with NAFLD stratified by the rs35761398 CNR2
SNP encoding for the Q63R CB2 protein variant.
CNR2 rs35761398 variant
RR QR QQ p
N (%) 59 (50%) 46 (39%) 13 (11%)
Age (years) 10.262.7 10.262.6 9.962.5 0.92
Female 41 (69) 29(63) 7 (54) 0.52
BMI (centile) 95.066.3 95.564.9 91.769.4 0.15
Waist Circumference (cm) 85.1610.9 84.769.8 82.669.5 0.73
HOMA-IR index 2.161.1 3.162.6 2.661.5 0.04
ISI 4.162.0 3.962.3 3.261.4 0.37
Glucose (mg/dl) 82.7612.3 85.0614.4 80.165.5 0.90
Hypertension 22 (37) 15 (32) 4 (31) 0.84
IGT or diabetes 29 (49) 22 (48) 8 (61) 0.67
Total Cholesterol (mg/dl) 164.6635 157.1633.3 170.4639.5 0.37
Triglycerides (mg/dl) 113.9671.9 98.7656.1 139.2660.2 0.12
ALT (IU/ml) 86.4659.7 88.9663.2 92.6651.6 0.94
AST (IU/ml) 56.9626.2 54.4626.2 60.8620.9 0.71
Gamma-GT (IU/ml) 33.9.621.7 30.3616.8 32.8622.5 0.64
Values are expressed as means 6 standard deviations or as numbers and
percentages. Mean values are compared by analysis of ANOVA. GLM analysis
including gender, age, waist circumference and HOMA-IR as covariates has
been used to compare continuous variables. Abbreviations: BMI: Body Mass
Index; HOMA-IR: homeostatic model of assessment of insulin resistance; ISI:
insulin sensitivity index; IGT: Impaired Glucose Tolerance; ALT: alanine
transaminase; AST: aspartate transaminase; Gamma-GT: Gamma-Glutamyl
transferase.
doi:10.1371/journal.pone.0042259.t002
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inflammatory switch, induces the transcription of inflammatory
cytokines, including TNFa and IL-6, in the hepatocytes and in the
Kupffer cells [26].
The production of these inflammatory cytokines seems to play a
major role in the further step from steatosis to steatohepatitis
progression.
The well-know effects of CB2 receptor on both peripheral and
central inflammatory response and mainly its ability to modulate
both activation of NF-kB and the production of TNFa and IL-6
appear of particular interest in the context of the study we have
performed. Experimental studies have, in fact, demonstrated that
CB2 stimulation is able to inhibit NF-kB translocation into the
nucleus, interfering with the phosphorylation of its activator, and
to decrease both TNFa and IL-6 production, enhancing the
expression of their synthesis inhibitor, the anti-inflammatory
cytokine IL-10 [27–29].
In 118 Italian children with biopsy-proven NAFLD, the CB2
variant carrying an arginine at codon 63 was not associated with
steatosis, but was associated with the severity of the NAFLD
inflammatory component, this increasing the risk for NASH
Figure 1. CNR2 rs35761398 genotype and severity of liver lesions. Relationship between the CNR2 rs35761398 genotype and the severity of
A) inflammation (grades 0–2) (p=0.0022); B) liver steatosis (grades 0–3) (p= 0.07); C) fibrosis (grades 0–3) (p = 0.24) in 118 children with NAFLD. P-
values less than 0.05 have been considered statistically significant. Age, sex, waist circumference and HOMA-IR index have been used as covariates.
doi:10.1371/journal.pone.0042259.g001
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appearence. In a previous study [16] we have shown, in a group of
obese children with liver steatosis at ultrasound imaging, the
presence of an association between the Q63R CB2 variant and
liver enzymes. In the present work we did not replicated this result.
The reason for this apparent discrepancy resides in the criteria
used, in this study, to enrol the patients. They are patients that
underwent liver biopsy and they show particularly high levels of
liver enzymes. This homogeneous increased level of ALT and
AST has not allowed to highlight the role of CB2 polymorphism in
modulating liver enzyme levels.
It has been recently demonstrated that the CB2 exhibiting an
arginine at codon 63 (R63) shows a reduced function when
activated by an endogenous cannabinoid ligand, compared to the
CB2 variant with the glutamine at the same codon (Q63) [30,31].
Therefore, the possibility exists that the protective modulating
effect exerted by a completely active CB2 system on liver
inflammation may be, at least partially, lost in the individual
carrying the allele encoding for CB2 R63.
Nevertheless the lack of association of CB2 polymorphism with
fibrosis may simply reflect the young age of the cohort (10.262.6)
as they have no sufficient time for the disease to progress.
Recently, the functional variant I148M of PNPLA3, a gene
likely involved in hepatic triglyceride hydrolisis, has been
associated with steatosis severity and with the presence of NASH
in the same cohort here studied [19]. In fact, whereas I148
PNPLA3 homozygous patients showed very mild and often
uncomplicated steatosis, heterozygous and homozygous M148
patients were strongly at risk of severe steatosis. Attempting to
delineate the role of genetic predisposition in NAFLD severity, we
suggest that PNPLA3 and CB2 may act in two different,
consecutive hits producing liver damage. PNPLA3 polymorphism
primitively predisposes to liver steatosis which in turn activates the
cascade of events leading to liver inflammation. CB2 polymor-
phism may work only later, when steatosis is already present and
NF-kB is up-regulated, modulating the transcription of several
inflammatory cytokines.
Accordingly, stratifying CB2 polymorphism on I148M PNPLA3
variant, we have noticed that the effect of R63 CB2 variant on
NASH appearance was emphasized in the sub-group of patients
carrying the M148 PNPLA3, which is associated to severe
steatosis.
The data reported in this work, therefore, may be explained by
the existence of different pathways contributing to liver damage
progression in NAFLD, suggesting an important role of the
inflammatory component in its pathogenesis and in its progression
towards more severe liver disease.
Considering that NAFLD is the most common cause of chronic
liver disease in children and given the highly heritable nature of
this disease [32], our results contributing to a better understanding
of the genetic factors involved in NAFLD severity may enable
Figure 2. CNR2 rs35761398 genotype and susceptibility to NASH. A) Relationship between the CNR2 rs35761398 genotype and the presence
of NASH in 118 children with NAFLD (p= 0.02). Fifty-three out of 118 patients show definitive NASH. Among these NASH subjects 2 were homozygous
for the CB2 Q63 allele, 23 were CB2 Q63R heterozygous and 28 homozygous for the CB2 R63. B) Relationship between the CNR2 rs35761398
genotype and the presence of NASH in 55 I148M PNPLA3 heterozygous children with NAFLD (p= 0.001). Among I148M PNPLA3 subjects 38 out of 55
show definitive NASH and were all QR or RR for the CB2 Q63R variant. Age, sex, waist circumference and HOMA-IR index have been used as
covariates.
doi:10.1371/journal.pone.0042259.g002
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improved identification of NAFLD children at risk for disease
progression and may help in the identification of new molecular
targets for pharmacological treatments.
Supporting Information
Table S1 Multivariate analysis incorporating both I148M
PNPLA3 and Q63R CB2 variants, as well as age, sex, waist
circumference and HOMA-IR.
(DOC)
Table S2 Odds ratio for liver disease features with respect the
Q63R CB2 variant. According to the data from the multivariate
analysis, odds ratio associated p-values were significant only for the
presence of NASH. It worth of notice that the odds ratio for
inflammation risk with respect the CB2 variant is 0 for the QQ
allele, since none of QQ subjects show a grade 2 of inflammation.
(DOC)
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